John Parkinson

In a population-based cohort study with a mean follow-up of 3.6 years, childhood outcomes showed no statistically significant associations with any adverse health conditions.

The company recently began its phase 2/3 trial for its investigational therapy.

With the US Centers for Disease Control and Prevention's recent change to mask guidance for vaccinated people, some confusion ensued and left state governments and businesses scrambling to react to the update.

The government agency will be assessing the safety and immunogenicity of an investigational nanoparticle influenza vaccine.

This is the first oral non-azole treatment for vaginal yeast infections.

If it is approved, this would be the first new antifungal class in the United States in years.

During the COVID-19 surge last year, the federal government stopped the required reporting on healthcare-associated infections (HAI) thus leaving an absence of data and important information on HAI. One study examined the effect the initial pandemic surge had on Clostridioides Difficile infection (CDI) in one hospital.

Do the very freedoms Americans enjoy allow us to make less than optimal choices? And will it prevent us from doing what medical science says is best if needed again?

The company plans to file for Food and Drug Administration (FDA) authorization for the 12-17 year old population in early June.

An investigational therapy demonstrated neutralizing antibodies as well as protection against the virus in preclinical trials.

A study looked at hospital admissions of Medicare patients and saw a large percentage of recurrent Clostridioides difficile infections (rCDI) as the primary diagnosis.

A diagnostic analyzer was studied looking at 3 biomarkers to predict the level of COVID-19, and could potentially serve as a risk stratification tool.

A large retrospective analysis of Medicare patients offers a glimpse of the incidence rates of this patient population and the burdens associated with it.

Study finds communicating on Electronic Medical Record (EMR) led to follow-up with infectious disease providers.

The federal agency elongates the time from 5 days up to 1 month for thawed out doses of the Pfizer-BioNTech vaccine.

A Roche test can be used in individuals not showing signs of symptomatic disease.

A new CDC study demonstrates effectiveness in a population with high exposure to the virus.

As the HIV population ages, a variety of health challenges may arise that typically happen in populations without chronic conditions.

With yesterday’s announcement, a lot of questions remain about how to proceed. One expert weighs in on this significant topic including how masks have substantially helped as a COVID-19 prevention strategy.

The United Kingdom is enrolling volunteers to be purposely exposed and infected with SARS-CoV-2 to learn more about infection, progression, and the immune response to it. A bioethics lawyer offers insights into the deliberation and decision-making that goes into whether human challenge trials should commence.

The CDC Director Rochelle Walensky confirmed the Pfizer-BioNTech vaccine can be administered in children as young as 12 years of age.

The company said its investigational therapy, ibrexafungerp, demonstrated superiority to placebo for treatment of vaginal yeast infections, and is working towards its Food and Drug Administration (FDA) Prescription Drug User Fee Act (PDUFA) date next month.

Vaxart enrolled its first participants for its dose-ranging and boosting regimen studies.

The Democratic Republic of the Congo (DRC) reached 42 days without a new case. Guinea, however, has not officially declared its outbreak over yet.

Investigators report the vaccine demonstrated it was safe, well-tolerated, and immunogenic in all age groups.

The companies are seeking approval for anyone aged 16 and above.

Company plans to initiate a rolling submission for US Food and Drug Administration (FDA) Biologics License Application (BLA) this month for the vaccine.

Moderna reports data demonstrating a single 50 µg shot of its mRNA-1273 or mRNA-1273.351 booster shot increased neutralizing titers against SARS-CoV-2, as well as the South African and Brazilian variants.

Amongst HIV negative participants, the vaccine demonstrated a 51% efficaciousness against B.1.351.

The company will provide the vaccine group with 34 million doses in the fourth quarter of this year, and up to 466 million more doses in 2022.